Both groups had fewer brain lesions than those in the placebo group and showed more than 30 percent reduction in the risk of disability progressing, compared with placebo, Merck said.
While the reduction in relapse rates were impressive, effect on progression of disability, which was the trial's secondary endpoint, was quite unimpressive.
Market Data 
Markets 
AI
